Modified Aldesleukin/Palivizumab Fusion Protein IOV-3001

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A fusion protein composed of a modified form of the recombinant interleukin-2 (IL-2) aldesleukin incorporated into the antibody palivizumab, with potential immunostimulating and antineoplastic activities. Upon administration of modified aldesleukin/palivizumab fusion protein IOV-3001, the modified aldesleukin moiety targets and binds to the IL-2 receptor (IL-2R) and activates IL-2/IL-2R-mediated signaling. This activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb), which enhances T-cell-mediated cytotoxic immune responses against tumor cells. The incorporation of aldesleukin into palivizumab increases the half-life of IOV-3001.

**Synonyms:** - IOV 3001 - IOV-3001 - IOV3001 - Modified Dimeric IL-2/Antibody Fusion Protein IOV-3001 - Modified IL-2 Fusion Protein IOV-3001 - Modified Interleukin-2 Fusion Protein IOV-3001